A U.S. research team has made progress toward creating a biomarker blood test that can detect esophageal cancer on the early side, a major need in order to combat the lethal disease.
Over the past year a clutch of startups have talked up their ability to automate aspects of R&D by matching software to robotic technologies. But the ambitions of some groups go well beyond these examples, with researchers aiming to create robo-chemists.
PatientsLikeMe is continuing to expand its business into new areas. Having struck its first broad R&D collaboration with a biopharma earlier this year, the online patient network has now given Actelion access to its community to create a new health outcome measure for a rare cancer.
Wet age-related macular degeneration is the leading cause of blindness in the developed world. The standard of care calls for about 8 costly injections into the eye of medication containing anti-VEGF (vascular endothelial growth factor) per year. "In the real world having patients maintain that level of monitoring and therapy just does not happen," Jim Taylor, who has struggled to convince his aging mother to receive the therapy, told FierceMedicalDevices in an interview.
Regeneron has again dialed up its R&D budget, spending more and more on a slew of late-stage assets that promise to line its pockets and an emerging crop of early drugs the Big Biotech believes can beat a path to blockbuster status.
BioDelivery Sciences International announced today that it will add about 80 patients to its Phase III pivotal trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy.
As part of a broader mandate for Philips to make itself more relevant in healthcare, Royal Philips and Accenture have created proof-of-concept software to enable anyone with limited muscle or speech function to better interact with the world around them.
A team of MIT researchers successfully tested a thin-film drug delivery system enabling steady, sustained release of medication for about 14 months, a scientific advancement with major commercial implications.
Christophe Weber, Takeda's anointed next CEO, sees a brighter future through specialization for the Japanese drugmaker, promising to focus only on therapeutic areas where it can lead, leaving behind losing programs.
One of the authors of a controversial and now-retracted paper purporting a stem cell breakthrough has been found dead in what appears to be a suicide, according to numerous reports, following an investigation that has alarmed researchers and rattled one of Japan's most respected institutions.